Evidence map›Paper›PMID 41659592›Full record

ArticlebioRxiv : the preprint server for biology2026

Volumetric mechanoplasticity couples melanoma drug tolerance to susceptibility to CD8

Xingjian Zhang, Dingyao Zhang, Xiangyu Gong, Andrew Peiran Yu, Rakesh K Jain, Lance L Munn, Michael Mak

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xingjian ZhangDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0003-1369-6556
Dingyao ZhangDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0001-9273-7824
Xiangyu GongDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0003-4033-9570
Andrew Peiran YuEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0009-0000-1682-5232
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-7571-3548
Lance L MunnEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michael MakDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0001-6881-8130

Funding

Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
TRANSFER GRANT: Systems Biophysics of Multiscale State Transitions in Cells and TissuesR35GM142875 · NIGMS · YALE UNIVERSITY · PI Michael MAK · 2021 to 2026
$2.7M
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3M
Systems Biology of Antigen and T-Cell Transport in Cancer ImmunotherapyR01CA284603 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Lance L. Munn, TIMOTHY P PADERA · 2023 to 2026
$1.9M
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastomaR01CA269672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Rakesh K. Jain · 2022 to 2026
$1.9M
Vascularized tumor explants for drug testingR01CA247441 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L. · 2021 to 2025
$1.9M
Critical Issues in the Tumor MicroenvironmentR13CA306205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2025 to 2025
$50k
NCI NIH HHS R01 CA247441NCI NIH HHS R01 CA259253NCI NIH HHS R01 CA269672NCI NIH HHS R01 CA284603NCI NIH HHS R13 CA306205NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NIGMS NIH HHS R35 GM142875
6 · The paper itself

Abstract

Cell swelling has been reported in physiological tumor contexts, but whether sustained cell volume expansion leaves a durable state that reshapes drug and immune responses in melanoma is unknown. Using controlled hypotonic dilution as an experimental handle, we compare two priming regimens with comparable hypotonic exposure but different magnitude and persistence of volume expansion, enabling us to test which post-recovery phenotypes track with sustained enlargement beyond hypotonic exposure alone. Sustained enlargement produces a measurable size imprint after return to isotonic conditions, accompanied by nuclear lamina and chromatin remodeling with p53 pathway engagement and suppression of replication and growth programs. After recovery, primed cells reinforce F-actin organization, migrate faster in 3D collagen, and induce antioxidant and anti-ferroptosis defenses consistent with improved stress survival. A gene expression signature derived from this response is associated with poorer outcome in TCGA skin cutaneous melanoma. Unexpectedly, the same volume history also increases IFN-γ response, elevates MHC-I, reduces sialylation, and increases susceptibility to CD8

Identifiers

PMID41659592
PMCPMC12873804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.